Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biologics
Biotech
Novartis inks $3.2B subcutaneous delivery deal with Alteogen
Novartis joins Biogen and GSK on the list of drugmakers to pay to access Alteogen's technology this year.
Nick Paul Taylor
Sep 2, 2026 7:51am
Takeda strikes Innovent pact worth up to $11.4B
Oct 22, 2025 9:15am
Hansoh, Chugai ink separate and lucrative licensing agreements
Oct 17, 2025 11:04am
Gilead lays off 36 people after axing Oceanside expansion plan
Jun 16, 2025 9:53am
SpliceBio secures $135M series B for eye gene therapy trials
Jun 11, 2025 3:00am
To Gilead's new CMO, pipeline diversification is key
Jun 9, 2025 10:00am
